Nutex Health (NASDAQ:NUTX) Issues Quarterly Earnings Results, Beats Estimates By $4.63 EPS

Nutex Health (NASDAQ:NUTX) posted its quarterly earnings data on Thursday. The company reported $9.58 EPS for the quarter, beating the consensus estimate of $4.95 by $4.63, Zacks reports. Nutex Health had a return on equity of 23.50% and a net margin of 10.95%.

Nutex Health Price Performance

Nutex Health stock traded down $5.33 during mid-day trading on Thursday, reaching $151.93. The company had a trading volume of 180,920 shares, compared to its average volume of 170,820. Nutex Health has a 1 year low of $77.21 and a 1 year high of $204.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.14 and a quick ratio of 3.12. The company has a market capitalization of $1.05 billion, a P/E ratio of 11.74 and a beta of 0.24. The stock’s 50-day simple moving average is $156.14 and its 200-day simple moving average is $128.98.

Hedge Funds Weigh In On Nutex Health

Several hedge funds have recently bought and sold shares of NUTX. BNP Paribas Financial Markets grew its stake in Nutex Health by 966.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock valued at $40,000 after acquiring an additional 290 shares during the last quarter. Royal Bank of Canada raised its position in Nutex Health by 752.4% during the fourth quarter. Royal Bank of Canada now owns 358 shares of the company’s stock worth $59,000 after acquiring an additional 316 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Nutex Health by 6,590.3% in the fourth quarter. Bank of America Corp DE now owns 2,074 shares of the company’s stock valued at $66,000 after purchasing an additional 2,043 shares in the last quarter. Vestcor Inc purchased a new stake in shares of Nutex Health in the third quarter valued at about $111,000. Finally, Osaic Holdings Inc. grew its position in shares of Nutex Health by 280.3% in the fourth quarter. Osaic Holdings Inc. now owns 810 shares of the company’s stock valued at $133,000 after purchasing an additional 597 shares during the last quarter. 5.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NUTX has been the topic of a number of analyst reports. B. Riley Financial started coverage on Nutex Health in a report on Friday, June 26th. They issued a “buy” rating and a $290.00 price objective on the stock. Zacks Research raised Nutex Health to a “hold” rating in a research note on Monday, June 29th. Weiss Ratings raised Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, July 28th. Wall Street Zen downgraded Nutex Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Finally, Lake Street Capital assumed coverage on Nutex Health in a report on Tuesday, June 2nd. They set a “buy” rating and a $235.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.33.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.